Before BMO, he held investment banking roles at JMP Securities and Stout, where he provided advisory services, including for capital raising and M&A activities, to companies across a wide range of sectors.Ĭox earned a Master of Business Administration from the University of Chicago and a Bachelor of Business Administration in finance from the University of Notre Dame. Cox also previously spent time on Horizon’s business development team, where he supported multiple acquisitions, financings and licensing transactions.īefore joining Horizon, Cox was vice president, capital markets at BMO Capital Markets, where he advised clients on debt financing transactions across various levels of the capital structure. Read moreĪaron Cox joined Horizon in 2016 and has served in various roles across finance, business development and corporate development, including as executive vice president, finance chief of staff for the chairman, president and chief executive officer and senior vice president, corporate development, where he had responsibilities spanning financial planning, corporate strategy, mergers and acquisitions (M&A), acquisition integration, capital markets planning, real estate, security and investor relations. She also brings vast experiences in sales, sales leadership, patient services, training and management and leadership development from her roles at MedImmune, Genentech, Merck and Wyeth.Īllison earned her Bachelor of Science in Business Administration in human resources from Ohio State University. in 2020.īefore joining Horizon, Allison was the head of patient access at Spark Therapeutics Inc., where she was responsible for creating and implementing the patient access strategy and process for the company’s first gene therapy launch. She also played a significant leadership role in the launch of TEPEZZA in the U.S. Allison previously led patient services for Horizon’s three rare disease brands and infused brands (TEPEZZA, KRYSTEXXA and UPLIZNA), as well as managed site of care. trade and distribution, access strategy and marketing, patient services, site of care, payor engagement, reimbursement strategy and patient engagement. market access team, which focuses on U.S. Kelley Allison joined Horizon in February 2018 and has served in various leadership roles in patient access and site of care throughout her time with the company. He previously served as chairman of the board of directors of Exicure Inc., a public clinical-stage biotechnology company, from 2019 to 2022 and on the board of directors of Aurinia Pharmaceuticals Inc., a public biopharmaceutical company, from 2020 to 2022 Raptor Pharmaceutical Corp., a public biopharmaceutical company, from 2010 to 2014 XOMA Corporation, a public biotechnology company, from 2011 to 2017 and Sucampo Pharmaceuticals Inc., a public biopharmaceutical company, from 2016 to 2018. Walbert is also a member of the National Organization for Rare Disorders (NORD) Advisory Board, the Wall Street Journal CEO Council and serves on the Board of Trustees of Muhlenberg College. He serves on the boards of Century Therapeutics Inc., Mirum Pharmaceuticals Inc. Walbert received his Bachelor of Arts in business from Muhlenberg College in Allentown, Pa.
From 1991 to 1998, he also held sales and marketing roles with increasing responsibility at G.D. From 1998 to 2001, Walbert served as director, CELEBREX North America, and arthritis team leader, Asia Pacific, Latin America and Canada, at G.D. From 2001 to 2005, he served as divisional vice president and general manager, immunology, at Abbott, now AbbVie, leading the global development and launch of the multi-indication biologic HUMIRA, and served as divisional vice president, global cardiovascular strategy. Before IDM, Walbert served as executive vice president, commercial operations at NeoPharm Inc., a public biopharmaceutical company. Before joining Horizon, he served as president, chief executive officer and director of IDM Pharma Inc., a public biopharmaceutical company which was acquired by Takeda America Holdings Inc., or Takeda, in June 2009. Tim Walbert joined Horizon in June 2008 as president and chief executive officer and has served as chairman of the company’s board of directors since 2010.
0 kommentar(er)
